Detalhe da pesquisa
1.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
J Thorac Oncol
; 18(11): 1581-1593, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541389